Whole genome analysis of an MDR Beijing/W strain of Mycobacterium tuberculosis with large genomic deletions associated with resistance to isoniazid

Gene

Volumn 582, Issue 2, 2016, Pages 128-136

  Zhang, Qiufen ^a   Wan, Baoshan ^a   Zhou, Aiping ^b   Ni, Jinjing ^a   Xu, Zhihong ^a   Li, Shuxian ^a   Tao, Jing ^a   Yao, YuFeng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Tongji University   (China)

Author keywords

Beijing W genotype; Genome sequencing; Isoniazid resistance; Large sequence polymorphisms; Mycobacterium tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ARTICLE; CASE REPORT; CELL MOTILITY; CHINA; CONTROLLED STUDY; CYTOKINE RESPONSE; GENE DELETION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC BACKGROUND; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HUMAN; IMMUNE RESPONSE; INDEL MUTATION; LIPID METABOLISM; LUNG TUBERCULOSIS; MACROPHAGE; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; OPEN READING FRAME; OPERON; PHYLOGENY; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; START CODON; STOP CODON; WHOLE GENOME ANALYSIS; BACTERIAL GENOME; DNA SEQUENCE; DRUG EFFECTS; GENETICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHENOTYPE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

BASE SEQUENCE; GENOME, BACTERIAL; GENOTYPE; HUMANS; INDEL MUTATION; ISONIAZID; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PHYLOGENY; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84959544696     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2016.02.003     Document Type: Article

References (46)

1. Alland D., et al. Role of large sequence polymorphisms (LSPs) in generating genomic diversity among clinical isolates of Mycobacterium tuberculosis and the utility of LSPs in phylogenetic analysis. J. Clin. Microbiol. 2007, 45(1):39-46.
2. Brosch R., et al. Use of a Mycobacterium tuberculosis H37Rv bacterial artificial chromosome library for genome mapping, sequencing, and comparative genomics. Infect. Immun. 1998, 66(5):2221-2229.
3. Camus J.C., et al. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002, 148(Pt 10):2967-2973.
4. Chen J., et al. Deletion-targeted multiplex PCR (DTM-PCR) for identification of Beijing/W genotypes of Mycobacterium tuberculosis. Tuberculosis (Edinb.) 2007, 87(5):446-449.
5. Cole S.T. Rifamycin resistance in mycobacteria. Res. Microbiol. 1996, 147(1-2):48-52.
6. Cole S.T., et al. Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393(6685):537-544.
7. Cuevas-Cordoba B., et al. Mutation at embB codon 306, a potential marker for the identification of multidrug resistance associated with ethambutol in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2015, 59(9):5455-5462.
8. Daim S., et al. Expression of the Mycobacterium tuberculosis PPE37 protein in Mycobacterium smegmatis induces low tumour necrosis factor alpha and interleukin 6 production in murine macrophages. J. Med. Microbiol. 2011, 60(Pt 5):582-591.
9. Domenech P., et al. The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J. Biol. Chem. 2004, 279(20):21257-21265.
10. Druszczynska M., et al. Monocyte signal transduction receptors in active and latent tuberculosis. Clin. Dev. Immunol. 2013, 2013:851452.
11. Forrellad M.A., et al. Role of the Mce1 transporter in the lipid homeostasis of Mycobacterium tuberculosis. Tuberculosis (Edinb.) 2014, 94(2):170-177.
12. Gagneux S. Genetic diversity in Mycobacterium tuberculosis. Curr. Top. Microbiol. Immunol. 2013, 374:1-25.
13. Guenin-Mace L., Simeone R., Demangel C. Lipids of pathogenic Mycobacteria: contributions to virulence and host immune suppression. Transbound. Emerg. Dis. 2009, 56(6-7):255-268.
14. Hershberg R., et al. High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol. 2008, 6(12).
15. Heym B., et al. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol. Microbiol. 1995, 15(2):235-245.
16. Iwamoto T., et al. Population structure analysis of the Mycobacterium tuberculosis Beijing family indicates an association between certain sublineages and multidrug resistance. Antimicrob. Agents Chemother. 2008, 52(10):3805-3809.
17. Kaimer C., Graumann P.L. Bacillus subtilis CinA is a stationary phase-induced protein that localizes to the nucleoid and plays a minor role in competent cells. Arch. Microbiol. 2010, 192(7):549-557.
18. Kawasaki N., et al. Targeted delivery of Mycobacterial antigens to human dendritic cells via Siglec-7 induces robust T cell activation. J. Immunol. 2014, 193(4):1560-1566.
19. Kozhamkulov U., et al. Molecular characterization of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Kazakhstan. Jpn. J. Infect. Dis. 2011, 64(3):253-255.
20. Langendam M.W., et al. Prevalence of inappropriate tuberculosis treatment regimens: A systematic review. Eur. Respir. J. 2012, 39(4):1012-1020.
21. Lew J.M., et al. TubercuList - 10 years after. Tuberculosis (Edinb.) 2011, 91(1):1-7.
22. Mariam D.H., et al. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2004, 48(4):1289-1294.
23. Masure H.R., et al. Membrane targeting of RecA during genetic transformation. Mol. Microbiol. 1998, 27(4):845-852.
24. Moro M.L., et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS 1998, 12(9):1095-1102.
25. Nodieva A., et al. Recent nosocomial transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2010, 14(4):427-433.
26. O'Brien K.L., et al. Evaluation of inhA gene and catalase-peroxidase gene among isoniazid-sensitive and resistant Mycobacterium tuberculosis isolates. Mol. Cell. Probes 1996, 10(1):1-6.
27. Oliveira J.S., et al. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex. Curr. Pharm. Des. 2006, 12(19):2409-2424.
28. Pedersen C., Kolmos H.J., Nielsen J.O. [Tuberculosis and the HIV pandemic. Risk of nosocomial tuberculosis infection]. Ugeskr. Laeger 1997, 159(9):1233-1238.
29. Prasad R. Multidrug and extensively drug-resistant TB (M/XDR-TB): problems and solutions. Indian J. Tuberc. 2010, 57(4):180-191.
30. Ramaswamy S.V., et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2003, 47(4):1241-1250.
31. Sampson S.L. Mycobacterial PE/PPE proteins at the host-pathogen interface. Clin. Dev. Immunol. 2011, 2011:497203.
32. Santangelo M.P., et al. Negative transcriptional regulation of the mce3 operon in Mycobacterium tuberculosis. Microbiology 2002, 148(Pt 10):2997-3006.
33. Sinha S.C., et al. Origin of asymmetry in adenylyl cyclases: Structures of Mycobacterium tuberculosis Rv1900c. EMBO J. 2005, 24(4):663-673.
34. Sintchenko V., et al. Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia. Pathology 1999, 31(3):257-260.
35. Siu G.K., et al. An upstream truncation of the furA-katG operon confers high-level isoniazid resistance in a Mycobacterium tuberculosis clinical isolate with no known resistance-associated mutations. Antimicrob. Agents Chemother. 2014, 58(10):6093-6100.
36. Tomioka H., Namba K. [Development of antituberculous drugs: Current status and future prospects]. Kekkaku 2006, 81(12):753-774.
37. Tracevska T., et al. Characterisation of rpsL, rrs and embB mutations associated with streptomycin and ethambutol resistance in Mycobacterium tuberculosis. Res. Microbiol. 2004, 155(10):830-834.
38. Tsolaki A.G., et al. Functional and evolutionary genomics of Mycobacterium tuberculosis: Insights from genomic deletions in 100 strains. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(14):4865-4870.
39. van der Werf M.J., et al. Multidrug resistance after inappropriate tuberculosis treatment: A meta-analysis. Eur. Respir. J. 2012, 39(6):1511-1519.
40. Wang F.L., et al. [Serum sialic acid level (SSAL) in patients with cancer or tuberculosis of the lung (author's transl)]. Zhonghua Zhong Liu Za Zhi 1981, 3(3):177-180.
41. Wong S.Y., et al. Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2011, 55(6):2515-2522.
42. Wu W., et al. A genome-wide analysis of multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis Beijing genotype. Mol. Gen. Genomics. 2013, 288(9):425-436.
43. Xu Y., et al. PPE57 induces activation of macrophages and drives Th1-type immune responses through TLR2. J. Mol. Med. (Berl.) 2015, 93(6):645-662.
44. Yang C., et al. Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China. Clin. Infect. Dis. 2012, 55(9):1179-1187.
45. Zhang Y., et al. Complete genome sequences of Mycobacterium tuberculosis strains CCDC5079 and CCDC5080, which belong to the Beijing family. J. Bacteriol. 2011, 193(19):5591-5592.
46. Zumla A., et al. The WHO 2014 global tuberculosis report-further to go. Lancet Glob. Health 2015, 3(1):e10-e12.